Resveratrol in Type2 Diabetes and Obesity

Stopped early · Not applicable · Has a placebo group

Conditions studied: Type 2 Diabetes, Obesity, Insulin Resistance

In brief

The main objective of this study is to investigate the effect of resveratrol (plant derived food supplement) on inflammatory mediators and insulin resistance at the cellular and molecular level in obese non diabetic and type 2 diabetic subjects in vivo.

Key facts

Study ID

NCT01158417

Run by

University at Buffalo

People needed

15

Starts

2008-12-01

Expected to finish

2012-07-08

Last updated by the study team

2022-11-09

Who can join

Age: 20 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 20 years of age and older
• Healthy Obese subjects with BMI > 30
• Type 2 Diabetics with BMI > 30
• Subjects with good peripheral vein.
• Subjects on statins, ACE inhibitors and thiazolidenediones will be allowed as long as they are on stable doses of these compounds and the dosage is not changed during the course of study.

You may not qualify if…

• Subjects on any antioxidant medication
• Patient on non-steroidal anti-inflammatory drug
• On any agent with significant antioxidant properties.
• History of drug or alcohol abuse
• Any life threatening disease
• Allergy to peanuts, grapes, wine, mulberries.
• Pregnant women.
• Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks.
• Subjects on anticoagulants.

Where it is running

• Jeanne Hejna — Williamsville, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.